What is Kayentis?
Established in 2003, Kayentis specializes in the collection of clinical trial data, providing sophisticated eCOA (electronic Clinical Outcome Assessment) solutions. The company has evolved from a niche provider into a comprehensive service partner, facilitating the transition toward decentralized and hybrid clinical trials. Its platform is engineered to support the post-pandemic operational environment, integrating seamlessly with telehealth services, mobile applications, and external medical devices. By simplifying the data capture process for both patients and clinical sites, Kayentis occupies a vital position in the digital health ecosystem, enabling more agile and patient-centric research methodologies.
How much funding has Kayentis raised?
Kayentis has raised a total of $25.5M across 5 funding rounds:
Series C
$6.2M
Unspecified
$1.6M
Private Equity
$3.9M
Private Equity
$8.3M
Other Financing Round
$5.4M
Series C (2007): $6.2M with participation from Seventure Partners
Unspecified (2015): $1.6M, investors not publicly disclosed
Private Equity (2016): $3.9M supported by Innovation Capital and Extens
Private Equity (2020): $8.3M featuring LBO France, Bpifrance, and Extens
Other Financing Round (2023): $5.4M backed by Extens, LBO France, and Bpifrance
Key Investors in Kayentis
Extens
Extens is a French private equity investment fund focused exclusively on healthcare software, aiding the growth of high-potential companies in the e-health sector.
LBO France
LBO France is a leading investment firm with over 30 years of expertise, focusing on mid-cap investments and innovative sectors including digital health.
Bpifrance
Bpifrance is a French public investment bank that supports companies at every stage of development through credit, guarantees, and equity financing.
What's next for Kayentis?
With the infusion of $5.4M, Kayentis is well-positioned to accelerate its product roadmap and expand its footprint in the decentralized clinical trial market. The strategic focus will likely center on enhancing interoperability between its eCOA solutions and broader digital health ecosystems, further reducing the burden on clinical trial participants. As the industry shifts toward more integrated, technology-driven research, Kayentis is expected to leverage its deep domain expertise to capture additional market share. The ongoing support from its core investor base provides the necessary stability to pursue long-term innovation, potentially exploring advanced analytics or AI-driven insights to further streamline the clinical development lifecycle.
See full Kayentis company page
